Another bidder, which remains unidentified, dropped out of the bidding process. Analysts at William Blair now think it unlikely that another suitor could offer a counter-proposal to Merck’s outstanding $6.7 billion acquisition offer.
Merck Chopped $1B Off Terns’ Offer After Seeing Updated Leukemia Data